Celcuity Secures FDA Nod for REVTORPYK, Eyes Expanded Breast Cancer Market
Event summary
- Celcuity's REVTORPYK (gedatolisib) received FDA approval on July 14, 2026 for HR+/HER2- PIK3CA Wild-Type advanced breast cancer.
- NCCN® recommended REVTORPYK as a preferred Category 1 option for second-line therapy in HR+/HER2- advanced breast cancer.
- Celcuity completed a $575.0 million convertible note offering, with net proceeds of $557.2 million.
- Phase 3 VIKTORIA-1 trial's PIK3CA mutant cohort achieved primary endpoint, doubling survival likelihood without disease progression or death compared to alpelisib plus fulvestrant.
The big picture
Celcuity's FDA approval and NCCN® recommendation position REVTORPYK as a key player in the HR+/HER2- advanced breast cancer market. The company's strategic focus on expanding clinical trials and securing additional regulatory approvals underscores its ambition to dominate this niche. With substantial funding secured, Celcuity is well-positioned to scale commercial operations and potentially expand into other oncology indications.
What we're watching
- Regulatory Expansion
- Whether Celcuity can secure supplemental FDA approval for the PIK3CA mutant cohort by Q3 2026.
- Market Penetration
- The pace at which REVTORPYK gains market share in the HR+/HER2- advanced breast cancer segment.
- Clinical Pipeline
- How the expansion of the VIKTORIA-2 trial impacts the development timeline for first-line treatments.
Related topics